Treatment of ocular disease
A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 μg/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/ml to about 200 μg/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.
1. A method to treat a posterior segment ocular condition selected from diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration in a patient comprising intraocularly administering a composition comprising a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof, the drug at a concentration up to about 200 μg/ml in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition without substantial toxicity wherein the composition is administered by at least one of intraocular injection.
2. The method of claim 1 wherein the composition further comprises Cyclosporin A, tacrolimus, or combinations thereof.
3. A method to treat a posterior segment ocular condition selected from diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration in a patient comprising intraocularly administering a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition by a method selected from the group consisting of topical administration at a concentration of about 50 pg/ml to less than 1 μg/ml, subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 μg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 μg/ml, or retrobulbar injection at a dose in the range of about 20 μg/ml to about 200 μg/ml.
4. The method of claim 3 wherein injection is intravitreal at a dose of about 50 μg/0.1 ml.
5. An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200 μg/ml by at least one of intraocular injection, or the composition is administered topically at a concentration in the range between about 50 pg/ml to less than 1 μg/ml.
6. The method of claim 5 wherein the composition is administered by subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 μg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 μg/ml, or retrobulbar injection at a dose in the range of about 20 μg/ml to about 200 μg/ml.
7. An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200 μg/ml by at least one of intraocular injection, or the composition is administered topically at a concentration in the range between about 50 pg/ml to less than 1 μg/ml.
8. The method of claim 7 wherein the composition is administered by subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 μg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 μg/ml, or retrobulbar injection at a dose in the range of about 20 μg/ml to about 200 μg/ml.
9. A method to treat an ocular condition in a patient comprising intraocularly administering to the patient a pharmaceutically acceptable formulation of a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof, in an amount up to about 200 μg/ml effective to treat an ocular condition selected from diabetic retinopathy, retinitis pigimentosa, or age related macular degeneration without substantial toxicity and at least one antibiotic, wherein the composition is administered by at least one of intraocular injection at a concentration up to about 200 μg/ml, or the composition is administered topically at a concentration in the range between about 50 pg/ml to less than 1 μg/ml.
10. A method to treat an ocular posterior segment condition selected from diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration in a patient comprising intraocularly administering a composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition by a method selected from the group consisting of topical administration at a concentration between about 50 pg/ml to less than 1 μg/ml, subconjunctival injection at a dose in the range of about 1 ng/ml to about 200 μg/ml, intravitreal injection at a dose in the range of about 1 ng/0.1 ml to about 200 μg/ml, or retrobulbar injection at a dose in the range of about 20 μg/ml to about 200 μg/ml.
11. The method of claim 10 wherein injection is intravitreal at a dose of about 50 μg/0.1 ml.